Enjoy complimentary customisation on priority with our Enterprise License!
According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration, as stated by the WHO. Depression can roughly be categorized into six different types. A patient with severe depression can have suicidal thoughts or behaviors. According to a 2012 WHO estimate, approximately 3,000 suicides take place each day, resulting in more than a million deaths per annum. Depression can be recurrent and can be severely debilitating for an individual. In patients with mild depression, the patient can be treated with medications, and in moderate or severe depression, a patient needs both medication and professional psychotherapy in terms of counseling. It has been reported by the WHO in 2008, that depression equally affects men and women, but women have a 50 percent higher tendency to get affected by depression than men. According to the CDC, depression can lead to adverse behavioral traits in an individual such as alcoholism, smoking, and sleep disturbance. According to the CDC fact sheet, one out of every 10 people is affected by depression in the US. The major depressive disorder is among the most debilitating disorders in the US, and affects approximately 14.8 million adults in the country, aged 18 years and above, according to the NIMH in the US. TechNavio's analysts forecast the Antidepressant market in the US to grow at a CAGR of [4.08] percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Antidepressant market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of depression. The Antidepressant market in the US is segmented based on the mechanism of action of the drugs used to treat depression, as illustrated below:
• Tricyclic Antidepressants
• Serotonin Norepinephrine Reuptake Inhibitors
• Selective Serotonin Reuptake Inhibitors
• Monoamine Oxidase Inhibitors
• Others
The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Antidepressant market in the US. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the antidepressant market size. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
Technavio’s report, Antidepressant Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the Antidepressant market in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
• Actavis
• Eli Lilly and Company
• GlaxoSmithKline
• Otsuka Pharmaceutical
• Pfizer
Other Prominent Vendors
• Abbott Laboratories
• AstraZeneca
• Aurobindo Pharma
• Bristol-Myers Squibb
• Dr. Reddy's Laboratories
• H. Lundbeck
• Janssen Pharmaceuticals
• Lupin
• Novartis
• Pierre Fabre
• Shire
• Somerset Pharmaceuticals
• Sun Pharmaceutical
• Sunovion Pharmaceuticals
• Takeda Pharmaceutical
• Teva Pharmaceutical
• Torrent Pharmaceuticals
• Valeant Pharmaceuticals
Market Driver
• Rise in Patient Population
• For a full, detailed list, view our report
Market Challenge
• Threat from Patent Expiries
• For a full, detailed list, view our report
Market Trend
• Growing Public Awareness
• For a full, detailed list, view our report
Get more value with Technavio’s subscription platform! Gain easy access to all of Technavio’s reports, along with on-demand services. Start your 14-day FREE trial
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Technavio also provides customized reports based on the specific requirement of our clients.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Celexa
04.1.2 Fetzima
04.1.3 Lexapro
04.1.4 Viibryd
04.1.5 Cymbalta
04.1.6 Prozac
04.1.7 Symbyax
04.1.8 Paxil
04.1.9 Wellbutrin
04.1.10 Abilify
04.1.11 Effexor
04.1.12 Pristiq
04.1.13 Zoloft
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disorder Overview
07.1 Depression & its Types
07.1.1 Major Depressive Disorder
07.1.2 Persistent Depressive Disorder
07.1.3 Psychotic Depression
07.1.4 Post-partum Depression
07.1.5 Seasonal Affective Disorder
07.1.6 Bipolar Disorder
07.2 Etiology
07.3 Epidemiology
07.3.1 Bipolar Disorder Among Adults
07.3.2 Dysthymic Disorder Among Adults
07.3.3 Major Depression Among Adults
07.3.4 Major Depression Among Adolescents
07.4 Treatment & Management
07.5 Economic Burden
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Mechanism of Action
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Competitive Assessment of the Top Drugs for Depression
17.2.2 Eli Lilly
17.2.3 Otsuka Pharmaceutical
17.2.4 Pfizer
17.2.5 GlaxoSmithKline
17.2.6 Actavis
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Actavis
18.1.1 Key Facts
18.1.2 Business Description
18.1.3 Business Segmentation
18.1.4 Business Segmentation by Revenue 2012 and 2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Information
18.1.8 SWOT Analysis
18.2 Eli Lilly
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation by Revenue
18.2.4 Sales by Geography
18.2.5 Business Strategy
18.2.6 Key Information
18.2.7 SWOT Analysis
18.3 GlaxoSmithKline
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Sales by Geography
18.3.6 Pipeline Products
18.3.7 Business Strategy
18.3.8 Key Information
18.3.9 SWOT Analysis
18.4 Otsuka Pharmaceutical
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2014
18.4.4 Business Segmentation by Revenue 2013 and 2014
18.4.5 Geographical Segmentation by Revenue 2014
18.4.6 Business Strategy
18.4.7 Recent Developments
18.4.8 SWOT Analysis
18.5 Pfizer
18.5.1 Key Facts
18.5.2 Business Overview
18.5.3 Business Segmentation by Revenue 2013
18.5.4 Business Segmentation by Revenue 2012 and 2013
18.5.5 Geographical Segmentation by Revenue
18.5.6 Business Strategy
18.5.7 Key Developments
18.5.8 SWOT Analysis
19. Other Reports in this Series
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.